Connecticut Allergy Patients Receive Free EpiPens
The state secured 10,000 devices as part of a settlement to improve local access to essential allergy medication.
Updated on Oct. 22, 2026 in Allergies
Live Poll
Should pharmaceutical companies face stricter penalties for significant price hikes on life-saving medications?
Connecticut has secured an $8 million settlement in an antitrust lawsuit against Mylan regarding alleged efforts to delay generic competition for EpiPens. As part of the agreement, the state is distributing 10,000 free EpiPens to 30 Federally Qualified Health Centers to improve access for patients.
Why it matters
The settlement addresses past concerns over high costs for epinephrine auto-injectors, which saw a 400 percent price increase in 2016. This distribution effort aims to provide necessary emergency allergy medication to residents at designated community health clinics across Connecticut.
The settlement follows allegations that Mylan blocked generic competitors, resulting in an $8 million penalty and 10,000 free EpiPens provided to the state. Mylan continues to deny all allegations of wrongdoing.
The players
Mylan
A pharmaceutical company that manufactures epinephrine auto-injectors used to treat life-threatening allergic reactions.
Connecticut Department of Public Health
The state agency responsible for overseeing the distribution of health resources and managing public health programs.
The details
EpiPens function by delivering a precise dose of epinephrine to treat severe allergic reactions, or anaphylaxis. By providing 5,000 two-packs to health centers, the state aims to maintain a steady supply of this life-saving rescue medication for patients who rely on the devices. The distribution is managed by the Connecticut Department of Public Health to reach clinics serving diverse populations.
Timeline
In 2016, the price of EpiPens increased by 400 percent.
On October 22, 2026, the Connecticut Attorney General announced the $8 million settlement.
Health Landscape
This settlement marks a legal resolution following years of scrutiny regarding the 2016 EpiPen price hike controversy. It reflects broader efforts to hold manufacturers accountable for practices that may limit access to essential allergy treatments.
If you struggle to afford emergency allergy medication, consult your physician about whether your local Federally Qualified Health Center has received the new supply. These resources are intended to ensure that patients have reliable access to life-saving epinephrine auto-injectors.
The takeaway
Reliable access to epinephrine is critical for anyone managing severe allergies or anaphylaxis. Always verify the expiration dates on your auto-injectors and discuss any concerns regarding medication affordability with your primary care provider.
Further reading
For more information on managing severe allergies, visit our Allergies section.
Live Poll
Should pharmaceutical companies face stricter penalties for significant price hikes on life-saving medications?
